(KURN) Kuros Biosciences - SW
Sector: Healthcare | Industry: Medical Devices | Exchange: SW (Switzerland) | Market Cap: 809m CHF | Total Return: -21.1% in 12m
Avg Turnover: 3.79M
Qual. Beats: 0
Rev. Trend: 94.9%
Warnings
P/E ratio 341.7
Tailwinds
No distinct edge detected
Kuros Biosciences AG is a Swiss-based biotechnology firm specializing in the commercialization of bone graft technologies for musculoskeletal care. The company operates primarily through its Medical Devices segment, focusing on its MagnetOs and Attrax product lines which utilize advanced surface topographies to promote bone healing in spinal and orthopedic procedures.
The biologics sector is characterized by high research and development costs and a rigorous regulatory approval process for class III medical devices. Kuros employs a specialized sales model targeting surgeons and hospitals in the United States and European Union, competing in a global bone graft substitutes market driven by an aging population and increasing spinal surgery volumes.
Further analysis of the companys competitive positioning is available on ValueRay. Kuros continues to transition from a research-focused entity into a commercial-stage organization by expanding its clinical data portfolio to support broader market adoption of its needle-shaped surface technology.
- MagnetOs revenue growth accelerates through US market share gains
- Direct sales force expansion improves medical device segment margins
- Clinical data validation drives surgeon adoption and competitive displacement
- Positive cash flow transition reduces future equity financing dilution risk
| Net Income: 1.64m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -5.04 > 1.0 |
| NWC/Revenue: 24.79% < 20% (prev 31.57%; Δ -6.79% < -1%) |
| CFO/TA -0.01 > 3% & CFO -733k > Net Income 1.64m |
| Net Debt (-10.3m) to EBITDA (10.2m): -1.01 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.0m) vs 12m ago 9.38% < -2% |
| Gross Margin: 87.02% > 18% (prev 87.98%; Δ -0.96% > 0.5%) |
| Asset Turnover: 135.1% > 50% (prev 89.37%; Δ 45.72% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBIT TTM 7.76m / Interest Expense TTM 6.55m) |
| A: 0.30 (Total Current Assets 65.5m - Total Current Liabilities 33.4m) / Total Assets 107.2m |
| B: -0.28 (Retained Earnings -29.9m / Total Assets 107.2m) |
| C: 0.08 (EBIT TTM 7.76m / Avg Total Assets 95.9m) |
| D: 1.66 (Book Value of Equity 66.9m / Total Liabilities 40.3m) |
| Altman-Z'' = 3.34 = A |
| DSRI: 1.24 (Receivables 31.8m/14.9m, Revenue 129.5m/75.6m) |
| GMI: 1.01 (GM 87.98% / 87.02%) |
| AQI: 0.82 (AQ_t 0.35 / AQ_t-1 0.43) |
| SGI: 1.71 (Revenue 129.5m / 75.6m) |
| TATA: 0.02 (NI 1.64m - CFO -733k) / TA 107.2m) |
| Beneish M = -2.41 (Cap -4..+1) = BBB |
As of June 19, 2026, the stock is trading at CHF 18.76 with a total of 370,682 shares traded.
Over the past week, the price has changed by -3.92%,
over one month by -2.58%,
over three months by -15.95% and
over the past year by -21.10%.
Kuros Biosciences has no consensus analysts rating.
Market Cap USD = 1.01b (808.5m CHF * 1.2511 CHF.USD)
P/E Trailing = 341.6667
P/S = 5.5355
P/B = 9.5703
Revenue TTM = 129.5m USD
EBIT TTM = 7.76m USD
EBITDA TTM = 10.2m USD
Long Term Debt = 3.58m USD (from longTermDebt, last quarter)
Short Term Debt = 517k USD (from shortTermDebt, last quarter)
Debt = 5.33m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.39m
Net Debt = -10.3m USD (calculated: Debt 5.33m - CCE 15.7m)
Enterprise Value = 1.00b USD (1.01b + Debt 5.33m - CCE 15.7m)
Interest Coverage Ratio = 1.19 (Ebit TTM 7.76m / Interest Expense TTM 6.55m)
EV/FCF = -353.7x (Enterprise Value 1.00b / FCF TTM -2.83m)
FCF Yield = -0.28% (FCF TTM -2.83m / Enterprise Value 1.00b)
FCF Margin = -2.19% (FCF TTM -2.83m / Revenue TTM 129.5m)
Net Margin = 1.26% (Net Income TTM 1.64m / Revenue TTM 129.5m)
Gross Margin = 87.02% ((Revenue TTM 129.5m - Cost of Revenue TTM 16.8m) / Revenue TTM)
Gross Margin QoQ = 85.36% (prev 88.74%)
Tobins Q-Ratio = 9.34 (Enterprise Value 1.00b / Total Assets 107.2m)
Interest Expense / Debt = 122.9% (Interest Expense 6.55m / Debt 5.33m)
Taxrate = 7.79% (304k / 3.90m)
NOPAT = 7.16m (EBIT 7.76m * (1 - 7.79%))
Current Ratio = 1.96 (Total Current Assets 65.5m / Total Current Liabilities 33.4m)
Debt / Equity = 0.08 (Debt 5.33m / totalStockholderEquity, last quarter 66.9m)
Debt / EBITDA = -1.01 (Net Debt -10.3m / EBITDA 10.2m)
Debt / FCF = 3.65 (negative FCF - burning cash) (Net Debt -10.3m / FCF TTM -2.83m)
Total Stockholder Equity = 65.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.71% (Net Income 1.64m / Total Assets 107.2m)
RoE = 2.49% (Net Income TTM 1.64m / Total Stockholder Equity 65.6m)
RoCE = 11.22% (EBIT 7.76m / Capital Employed (Equity 65.6m + L.T.Debt 3.58m))
RoIC = 10.55% (NOPAT 7.16m / Invested Capital 67.9m)
WACC = 8.20% (E(1.01b)/V(1.02b) * Re(8.24%) + (debt cost/tax rate unavailable))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 7.32%
[DCF] Fair Price = unknown (Cash Flow -2.83m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.90 | Revenue CAGR: 131.1% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.15 | Chg30d=-54.41% | Revisions=+20% | GrowthEPS=+222.1% | GrowthRev=+38.3%
EPS next Year (2027-12-31): EPS=0.43 | Chg30d=N/A | Revisions=+20% | GrowthEPS=+190.0% | GrowthRev=+42.4%
[Analyst] Revisions Ratio: +20%